Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930109 · ClinicalTrials.gov registry record · Phase 1
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
A Phase 1 study, sponsored by Prescient Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02930109 is a Phase 1 study that has completed, run by Prescient Therapeutics. The registered enrollment target is 33 participants.
The verdict
NCT02930109, a Phase 1 study, has completed, sponsored by Prescient Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.
Interventions
- DRUG Cytarabine
- DRUG PTX-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2024-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930109
The ClinicalTrials.gov registry entry for NCT02930109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prescient Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT02930109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02930109 about?
NCT02930109 is a clinical study titled "A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia". A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.
What is the current status of trial NCT02930109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2016-12-09. Estimated completion is 2024-03-04.
What interventions are being tested in trial NCT02930109?
The interventions under investigation include: Cytarabine (DRUG), PTX-200 (DRUG).
Who is sponsoring clinical trial NCT02930109?
This trial is sponsored by Prescient Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.